Skip to main content
Are you a healthcare professional?Join GLP1Zoom for HCPs →
GLP1ZoomFind provider

Saxenda guide

Saxenda for Weight Loss: Clinical Evidence

Saxenda weight-loss outcomes are well-documented in FDA pivotal trials. This page summarizes mean body-weight change versus placebo, timing to peak effect, BMI eligibility criteria, and how individual results vary. Editorial review based on published prescribing information.

Editorially reviewed 20 days ago8 min read

Saxenda weight-loss results

Saxenda produced 8% mean body-weight reduction in the SCALE pivotal trial at 56 weeks — substantially more than placebo and competitive with other approved weight-loss medications. This page details the clinical evidence, eligibility criteria, and what individual results look like in practice.

How effective is Saxenda?

Mean body-weight change at 56 weeks in the SCALE trial. Source: FDA prescribing information.

Saxenda8%
Placebo2.6%

Individual results vary. Trial participants also received lifestyle counseling. Full disclaimer.

Expected weight-loss curve

Mean body-weight change across 56 weeks on Saxenda from the SCALE trial. Curve smoothed from published endpoints; individual results vary significantly.

0%-5%-10%w0w4w8w12w20w36w52w56-8% at w56

Trial participants also received lifestyle counseling. Real-world results depend on dose adherence, side-effect tolerance, and lifestyle factors.

Eligibility criteria

Who Saxenda is for — and not for

Often a fit for

  • Adults with type 2 diabetes (Victoza)
  • Adults with BMI ≥30, or ≥27 with weight-related condition (Saxenda)
  • Patients who prefer daily dosing schedule

Not appropriate if

  • Personal or family history of medullary thyroid carcinoma
  • Multiple Endocrine Neoplasia syndrome type 2
  • Pregnancy or planning pregnancy
  • Type 1 diabetes
  • History of pancreatitis

Eligibility is determined by a licensed prescriber, not GLP1Zoom. See our medical disclaimer.

What individual results actually look like

Trial averages obscure huge individual variation. In SCALE:

  • The average participant lost ~8% of body weight
  • About 1 in 3participants lost >15% body weight
  • About 1 in 10participants lost <5% (low responders)
  • A small percentage gained weight or had no change

Predictors of better response include: starting BMI ≥ 35, adherence to dose schedule, concurrent lifestyle changes (reduced caloric intake, regular activity), and patient commitment to long-term treatment. Predictors of worse response include: dose reductions from side effects, sporadic adherence, and certain genetic variations under research.

Timing — when results show up

Early appetite reduction begins within 1-2 weeks of starting Saxenda. Visible weight loss usually starts at 4-8 weeks after reaching the second titration dose. Maximum effect plateaus around the trial endpoint timing (typically 56-72 weeks depending on the medication). Without continued treatment, regain occurs gradually — most patients regain 2/3 of lost weight within 1 year of stopping.

Saxenda vs other weight-loss approaches

Compared to other options:

  • vs lifestyle alone (diet+exercise): typical lifestyle programs produce 3-8% weight loss. Saxenda produces 8% — 2-4x more.
  • vs older weight-loss medications (phentermine, orlistat): produce ~5-7%. Saxenda substantially outperforms.
  • vs bariatric surgery: surgery typically produces 25-35% weight loss, permanent. Saxenda produces 8% with risk of regain on stopping. Surgery is more effective but irreversible.

Side effects affecting weight-loss outcomes

Side effects affect how much weight a patient actually loses:

  • Patients who reach the target dose with manageable side effects achieve maximum benefit
  • Patients who must stay at a lower-than-target dose (due to intolerable side effects) typically lose less weight
  • Patients who discontinue early due to side effects often regain rapidly

See our Saxenda side effects guide for management tactics that improve adherence.

Long-term outlook — what happens after a year?

Most clinical data for Saxenda covers 56-72 weeks. Longer-term safety and effectiveness data is accumulating. Key questions still being answered: Is the weight loss maintained at 2-5 years? Are there long-term safety signals not visible in 18-month trials? What happens to insulin sensitivity, cardiovascular events, and other outcomes long-term? Current guidance: treat Saxenda as a long-term medication (years), not a short course.

FAQ about Saxenda for weight loss

How fast does Saxenda work for weight loss?

Appetite reduction within 1-2 weeks; visible weight loss usually 4-8 weeks; maximum effect at 56 weeks per trial data.

Will I regain weight if I stop Saxenda?

Most patients regain about 2/3 of lost weight within 1 year of stopping, based on extension studies. This is why Saxenda is typically treated as a long-term medication rather than a short course.

What if Saxenda doesn't produce enough weight loss for me?

About 10% of patients are low responders (<5% weight loss at full dose). Options include: switching to a different GLP-1 (tirzepatide tends to produce more weight loss than semaglutide), adding adjunct therapy, or considering bariatric surgery if BMI warrants. See our alternatives guide.

Editorial summary based on FDA-approved trial data. Individual results vary. Full disclaimer.

For weight loss for other GLP-1 medications

Compare for weight loss guides across the GLP-1 family.